Welcome!

News Feed Item

ATL1102 for Stem Cell Mobilisation Trial Commencement

TOORAK, Australia, March 17, 2014 /PRNewswire/ -- Antisense Therapeutics (ASX:ANP) is pleased to advise that it has commenced dosing in its Phase I Stem Cell Mobilisation (SCM) Human Proof of Concept trial of ATL1102, the Company's second generation antisense drug targeting the VLA-4 receptor. The trial will assess the safety, tolerability and effect of ATL1102 on the release of hematopoietic stem cells (CD34+) into the blood when dosed alone and in combination with an existing therapy (Granulocyte Colony Stimulating Factor (G-CSF)). The randomised, open label study of ATL1102 dosed over 5 days (given on day 1, 3 and 5) in 10 healthy volunteers is being conducted by leading Clinical Research Organisation, Nucleus Network at its clinical trial unit at the Alfred Hospital, Melbourne, Victoria. (The Study "Protocol Synopsis" following this announcement provides further information).

With the necessary screening, dosing and follow up of patients, ANP anticipates that results from the trial will be reported mid 2014.

The mobilisation (release) of these stem cells from the bone marrow into the blood is part of an important medical procedure used to improve outcomes for patients undergoing chemotherapy to treat certain cancers. The stem cells released into the blood are then collected and stored before high dose chemotherapy and then re-infused to replace those lost during chemotherapy in order to re-establish the immune system. The basis for using ATL1102 in the SCM indication is related to the role of VLA-4 in regulating the release of CD34+ stem cells from the bone marrow, with another drug that also targets VLA-4 having been shown to increase CD34+ stem cell release in humans. In a previous study in Multiple Sclerosis patients, ATL1102 demonstrated similar activity to that drug by increasing CD34+ levels in the blood.

Dr Jason Lickliter, Medical Director of Nucleus Network and Principal Investigator for the trial said "This human Phase I trial of ATL1102 is designed to evaluate whether ATL1102 can improve mobilization of CD34+ stem cells when used in combination with standard mobilisation therapy to levels that would make it clinically beneficial for use in the collection of stem cells for transplantation. There is an acknowledged clinical need for increasing mobilisation levels beyond those achieved by the current therapeutic approach, and so I am very pleased to be working with Antisense Therapeutics to assess the merits of ATL1102 in this important clinical setting."

Antisense Therapeutics Limited CEO and Managing Director Mark Diamond said "The stem cell mobilisation opportunity for ATL1102 while commercially attractive with, by our estimation, a market potential of several hundred million dollars per annum, also presents as an excellent return on investment proposition given costs are expected to be relatively low for developing the drug in this  indication. We believe that positive outcomes from this trial will strongly enhance our drug's potential for this application and naturally we relish the opportunity to further develop a drug that can potentially provide better outcomes for cancer patients. We look forward to successfully conducting the study and to reporting results from this SCM trial which are anticipated mid-year."

Protocol Synopsis


Title

A Phase I, Randomised, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1102 Alone and in Combination with G-CSF in Healthy Volunteers

Study Number

1102SCM-CT01

Study Design

Single-centre, open-label, randomised, parallel group study

Objectives

  • To assess the safety and tolerability of subcutaneous doses of ATL1102 alone, and in combination with G-CSF in healthy volunteers
  • To assess the pharmacodynamics of ATL1102 alone, and in combination with G-CSF in healthy volunteers
  • To assess the pharmacokinetics of ATL1102 alone, and in combination with G-CSF in healthy volunteers

Endpoints

  • Safety and tolerability of ATL1102 in combination with G-CSF
  • Pharmacokinetic profiles of ATL1102
  • Pharmacodynamic measures including release of CD34+ haematopoietic stem cells and progenitor cells

Number of patients

It is planned that 10 patients will be randomised to one of 3 dosing groups for the study.

Key Patient Criteria

Healthy male volunteers between the ages of 18 and 50 years of age.  BMI between 19 and 32 kg/m2

Dosing

ATL1102 and G-CSF will be delivered as subcutaneous (s.c.) injections according to the following schedule:

  • Group A (n = 3) will receive Granulocyte-Colony Stimulating Factor (G-CSF; 10µg/kg/day) via s.c. administration on days 1, 2, 3, 4 and 5
  • Group B (n = 3) will receive ATL1102 (400 mg/day) via via s.c. administration on days 1, 3 and 5
  • Group C (n = 4) will receive G-CSF (10µg/kg/day) on days 1, 2, 3, 4 and 5 and ATL1102 (400 mg/day) on days 1, 3 and 5.

Per Patient Duration

Up to 28 days screening, one week dosing, one week follow up

Trial Location

Nucleus Network, Melbourne, VIC.

Principal Investigator

Dr Jason Lickiter

Trial Standard

GCP

 

About Stem Cell Mobilisation in Cancer treatment: stem cell mobilization and transplantation is a medical procedure used to improve clinical outcomes for patients undergoing chemotherapy to treat cancer.  Some chemotherapy has toxic effects on bone marrow, so hematopoietic stem cells are collected from the blood of the patient – or from a donor's blood – before the patient receives chemotherapy. These collected stem cells are then stored and given back later to replace those lost during chemotherapy (engraftment). There are normally only a small number of stem cells in the blood, so stem cell mobilization agents are used to increase this number before stem cell collection from a donor or more typically from a patient. Granulocyte colony-stimulating factor (G-CSF) is the main agent used for hematopoietic stem cell mobilization. While G-CSF is successful in mobilizing hematopoietic stem cells, there is often the need for additional complimentary mobilizing therapies. The major product used in combination with G-CSF is Mozobil® however there is an opportunity to improve on the level of stem cell release achieved with G-CSF alone or in combination with Mozobil.  At least 2 million CD34+ cells per kg are required for durable reconstitution of the immune system, however greater than 5 million CD34+ cells per kg, sourced in one or more collections, lead to improved engraftment and patient outcomes.

ATL1102 is a second generation antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). In inflammation, white blood cells (leukocytes) move out of the bloodstream into the inflamed tissue, for example, the Central Nervous System (CNS) in MS, and the lung airways in asthma. The inhibition of VLA-4 may prevent white blood cells from entering sites of inflammation, thereby slowing progression of the disease. VLA-4 is a clinically validated target in the treatment of MS. Antisense inhibition of VLA-4 has demonstrated positive effects in a number of animal models of inflammatory disease including MS with the MS animal data having been published in a peer reviewed scientific journal.  ATL1102 was previously shown by Antisense Therapeutics to be highly effective in reducing MS lesions in a Phase IIa clinical trial in MS patients.  The company has also lodged an International patent application on ATL1102 based on preliminary data in mice and humans supporting its' potential application as a stem cell mobilization agent for use in combination with G-CSF to improve the level of stem cell release achieved with G-CSF alone.

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals  Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with multiple  sclerosis (MS), ATL1103 a second-generation antisense drug designed to block GHr production and thereby lower blood  IGF-I levels and is in clinical development as a potential treatment for growth and other GH-IGF-I disorders, ATL1102  (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.

Contact Information:
Website: www.antisense.com.au 
Managing Director: Mark Diamond +61 (3) 9827 8999
USA Investor/Media: Joshua Drumm +(1) 212 375 2664; [email protected] 
Australia Investor/Media: Simon Watkin +61 (0)413 153 272; [email protected] 

 

SOURCE Antisense Therapeutics Limited

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management solutions, helping companies worldwide activate their data to drive more value and business insight and to transform moder...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. Big Data at Cloud Expo - to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace.
SYS-CON Events announced today the Enterprise IoT Bootcamp, being held November 1-2, 2016, in conjunction with 19th Cloud Expo | @ThingsExpo at the Santa Clara Convention Center in Santa Clara, CA. Combined with real-world scenarios and use cases, the Enterprise IoT Bootcamp is not just based on presentations but with hands-on demos and detailed walkthroughs. We will introduce you to a variety of real world use cases prototyped using Arduino, Raspberry Pi, BeagleBone, Spark, and Intel Edison. Y...
SYS-CON Events announced today that China Unicom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE F...
Major trends and emerging technologies – from virtual reality and IoT, to Big Data and algorithms – are helping organizations innovate in the digital era. However, to create real business value, IT must think beyond the ‘what’ of digital transformation to the ‘how’ to harness emerging trends, innovation and disruption. Architecture is the key that underpins and ties all these efforts together. In the digital age, it’s important to invest in architecture, extend the enterprise footprint to the cl...
Video experiences should be unique and exciting! But that doesn’t mean you need to patch all the pieces yourself. Users demand rich and engaging experiences and new ways to connect with you. But creating robust video applications at scale can be complicated, time-consuming and expensive. In his session at @ThingsExpo, Zohar Babin, Vice President of Platform, Ecosystem and Community at Kaltura, will discuss how VPaaS enables you to move fast, creating scalable video experiences that reach your...
I’m going to cry tonight, long and hard. I’ll do so as I remember and mourn Jeremy Geelan. I knew Jeremy for almost 20 years, from the time he showed up one day at Cloud Expo’s headquarters in Bergen County, New Jersey, and went to work. The show wasn’t called Cloud Expo then, of course – it was still known as Java Edge, a pioneering event that grabbed developers, architects, and enterprise IT users alike for twice-yearly confabs. Jeremy didn’t have a job there, or even a job offer. He was s...
Creating replica copies to tolerate a certain number of failures is easy, but very expensive at cloud-scale. Conventional RAID has lower overhead, but it is limited in the number of failures it can tolerate. And the management is like herding cats (overseeing capacity, rebuilds, migrations, and degraded performance). Download Slide Deck: ▸ Here In his general session at 18th Cloud Expo, Scott Cleland, Senior Director of Product Marketing for the HGST Cloud Infrastructure Business Unit, discusse...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said “No to LUNs.” With Tintri they mana...
DevOps at Cloud Expo, taking place Nov 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long dev...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...